Drug intelligence / Profile preview

sarin

Development stage
Unknown
Lead developer
I.G. Farben
Modality
Small Molecules
Administration
Inhalation, Topical, Oral, Ophthalmic
01

Overview

Sarin is an extremely toxic, synthetic organophosphorus compound classified as a nerve agent and chemical weapon. It was originally developed in Germany in 1938 as a potential pesticide but was later repurposed for military use due to its high potency. Sarin acts by irreversibly inhibiting the enzyme acetylcholinesterase, leading to accumulation of acetylcholine at neuromuscular junctions and synapses throughout the nervous system. This results in continuous stimulation of muscles, glands, and central nervous system structures, causing symptoms such as muscle twitching, respiratory failure, convulsions, paralysis, and death if not treated rapidly. Sarin is a clear, colorless liquid that can evaporate into vapor; it is odorless and tasteless in pure form. It has been used in warfare and terrorist attacks (notably the Tokyo subway attack), but its production and stockpiling are now banned under international law (Chemical Weapons Convention). Treatment for exposure includes rapid decontamination and administration of antidotes such as atropine and diazepam[1][3][5][7].

Other names
isopropyl methylphosphonofluoridateGBTriloneTrilon 46Trilon46Trilon-46
02

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on sarin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sarin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call